Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.
about
Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.Inhibitors: resolving diagnostic and therapeutic dilemmas.Treating haemophilia A with recombinant blood factors: a comparison.Haemophilia A: meeting the needs of individual patients.Joint protection in haemophilia.Development and introduction of recombinant factor VIII--a clinician's experience.Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series.Murine leukemia virus-derived retroviral vector has differential integration patterns in human cell lines used to produce recombinant factor VIII.Factor VIII inhibitor and source of replacement therapy.Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A.Six-month clinical observation on safety and efficacy of a full-length recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A.Reported inhibitor incidence in FVIII PUP studies: comparing apples with oranges?A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates.Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study.
P2860
Q31098999-94347C74-1607-4723-ABC2-8D0089F0D4D3Q33715399-90754201-DE21-4540-AFAE-6F77F2C2B6E3Q34636988-347DAEC8-502E-4A0F-A886-F944A0CBF06AQ35779195-3765E523-5311-4C41-86C1-7BF8C495C38CQ37008132-57C0515E-9B62-4924-9ABF-EBE442AA7E9FQ37912258-A347FC60-99F4-4200-8DF5-80603062DFE7Q38003396-B3F13B2C-559C-4ADD-9DF3-847FEA592417Q38958322-10660711-2A8D-4E63-861A-EEE0B89248CCQ38974765-49E5B7D4-06B2-49C2-986B-76DE00971715Q43056247-3176DAF0-E0FE-4662-8CA5-9E8BCDA8A8A0Q45863828-587C3E44-B560-423B-B3CC-58412C58C5F9Q45867869-7843898B-188E-4DA5-A100-54A0F40775A0Q45872702-8F280AA8-4F26-4BA0-AC0C-04E72FE79476Q45874428-A75F2933-624C-4472-A816-47C8C7FF045DQ45877732-9785503A-2E85-4B7B-885C-452B79B61EE7Q45877755-BBD0DAD0-F44B-4C28-86AE-9306199E4E53
P2860
Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Lack of evidence for increased ...... ed to recombinant factor VIII.
@ast
Lack of evidence for increased ...... ed to recombinant factor VIII.
@en
Lack of evidence for increased ...... ed to recombinant factor VIII.
@nl
type
label
Lack of evidence for increased ...... ed to recombinant factor VIII.
@ast
Lack of evidence for increased ...... ed to recombinant factor VIII.
@en
Lack of evidence for increased ...... ed to recombinant factor VIII.
@nl
prefLabel
Lack of evidence for increased ...... ed to recombinant factor VIII.
@ast
Lack of evidence for increased ...... ed to recombinant factor VIII.
@en
Lack of evidence for increased ...... ed to recombinant factor VIII.
@nl
P2860
P1433
P1476
Lack of evidence for increased ...... ed to recombinant factor VIII.
@en
P2093
Ehrlich HJ
Scharrer I
P2860
P304
P356
10.1046/J.1365-2516.2001.00515.X
P577
2001-07-01T00:00:00Z